NCT01329289: SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma |
|
|
| Withdrawn | 2 | 0 | US | SOM230, Pasireotide, Bortezomib, Velcade, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Maxidex, dexamethasone sodium phosphate, dexamethasone acetate | University of Pittsburgh, Novartis | Multiple Myeloma in Relapse, Multiple Myeloma | 02/12 | 02/12 | | |
NCT01234974: IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus |
|
|
| Withdrawn | 2 | 0 | US | Pasireotide, Pasireotide s.c., Pasireotide LAR, SOM230, Everolimus, RAD001 | Milton S. Hershey Medical Center | Multiple Myeloma | 12/12 | 12/13 | | |